179 related articles for article (PubMed ID: 35721889)
1. Future prospect of "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients".
Kang YB; Cai Y
World J Gastroenterol; 2022 May; 28(20):2248-2250. PubMed ID: 35721889
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
4. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
5. Research progress of gut microbiota in hepatocellular carcinoma.
Li K; Liu J; Qin X
J Clin Lab Anal; 2022 Jul; 36(7):e24512. PubMed ID: 35719048
[TBL] [Abstract][Full Text] [Related]
6. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
[No Abstract] [Full Text] [Related]
7. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.
Huo R; Chen Y; Li J; Xu Q; Guo J; Xu H; You Y; Zheng C; Chen Y
Curr Oncol; 2023 Feb; 30(2):1818-1830. PubMed ID: 36826102
[TBL] [Abstract][Full Text] [Related]
8. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.
Li L; Ye J
Medicine (Baltimore); 2020 Sep; 99(37):e21788. PubMed ID: 32925716
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
12. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
13. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.
Salgia NJ; Bergerot PG; Maia MC; Dizman N; Hsu J; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
Eur Urol; 2020 Oct; 78(4):498-502. PubMed ID: 32828600
[TBL] [Abstract][Full Text] [Related]
14. Expanding the immunotherapy roadmap for hepatocellular carcinoma.
Baretti M; Kim AK; Anders RA
Cancer Cell; 2022 Mar; 40(3):252-254. PubMed ID: 35290785
[TBL] [Abstract][Full Text] [Related]
15. Advanced papillary thyroid carcinoma responding to nivolumab.
Michel Ocampo M; Lerner J; Tosonian S; Dasanu CA
J Oncol Pharm Pract; 2021 Mar; 27(2):453-456. PubMed ID: 32507101
[TBL] [Abstract][Full Text] [Related]
16. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
17. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
[TBL] [Abstract][Full Text] [Related]
18. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota and immunotherapy of renal cell carcinoma.
Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]